Eli Lilly to acquire Orna Therapeutics in deal valued Up to $2.4 billion. Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., a biotechnology company focused on in vivo immune cell engineering using circular RNA technology. The acquisition strengthens Lilly's push into next-generation genetic medicines, particularly in vivo CAR-T therapies for autoimmune diseases - an area currently constrained by the cost and complexity of ex vivo cell therapy. Why Orna matters? Orna is developing a new therapeutic class based on: * Engineered circular RNA (oRNA) * Proprietary lipid nanoparticle (LNP) delivery systems This approach allows a patient's own body to generate cell therapies internally, potentially bypassing: * Cell extraction * Ex vivo manipulation * Re-infusion logistics Preclinical experiments suggest Orna's circular RNA platform may enable more durable protein expression than conventional linear mRNA, opening treatment possibilities not feasible with current RNA or cell therapy technologies. Lead program: in vivo CAR-T for autoimmune disease. Orna's lead asset, ORN-252, is a clinical trial-ready, CD19-targeted in vivo CAR-T therapy aimed at B cell - driven autoimmune diseases. Unlike traditional autologous CAR-T: * CAR-T cells are generated inside the patient * Manufacturing, time delays, and high costs may be significantly reduced * Broader patient access becomes feasible Lilly's strategic rationale. Lilly is targeting a known bottleneck in autoimmune CAR-T development. Dr. Francisco Ramírez-Valle, SVP and Head of Immunology Research and Early Clinical Development at Lilly, said early CAR-T studies have shown strong promise, but ex vivo approaches remain difficult to scale. He emphasized that Lilly sees Orna's platform as a way to: * Remove logistical barriers * Expand access to transformative therapies * Create an entirely new class of genetic medicines Orna's perspective. Dr. Joe Bolen, CEO of Orna Therapeutics, highlighted that the company's circular RNA and LNP platforms are designed to unlock in vivo CAR-T therapies across multiple B cell - driven autoimmune indications. He added that partnering with Lilly accelerates the ability to fully realize the technology's therapeutic potential. Deal terms at a glance. * Transaction type: Acquisition * Total potential value: Up to $2.4 billion * Structure: * Upfront cash payment * Additional milestone-based payments tied to clinical development Final accounting treatment will be determined by Lilly under GAAP and reflected in its financial results following closing. Advisors. * Legal counsel (Lilly): Paul, Weiss, Rifkind, Wharton & Garrison LLP * Financial advisor (Orna): Lazard * Legal counsel (Orna): Goodwin Procter LLP Bigger picture. This deal signals: * Lilly's serious commitment to in vivo cell therapy * Growing confidence in circular RNA as a next step beyond mRNA * A strategic shift toward scalable autoimmune CAR-T solutions If Orna's platform translates clinically, it could redefine how CAR-T therapies are delivered - moving from bespoke manufacturing to off-the-shelf, in-body generation.

Lilly acquires Orna Therapeutics to boost cell therapy innovations. Eli Lilly and Company has entered a definitive agreement to acquire Orna Therapeutics, a biotechnology firm based in Watertown, Massachusetts. This strategic acquisition, announced on February 9, 2026, aims to enhance Lilly's capabilities in cell therapy innovations, particularly focusing on treatments for B cell-driven autoimmune disorders. Lilly's acquisition of Orna Therapeutics. The agreement allows Lilly to acquire Orna for up to $2.4 billion. This total includes an upfront payment with further disbursements contingent upon the achievement of specific clinical development milestones. Lilly plans to reflect this transaction in its financial results and guidance upon closing. Innovations in cell therapy. Orna Therapeutics champions a new class of therapeutics designed with engineered circular RNA and novel lipid nanoparticles. This groundbreaking approach enables patients' bodies to create cell therapies aimed at treating underlying diseases. Orna's lead candidate, ORN-252, is a clinical trial-ready CAR-T therapy targeting CD19, which is intended for B cell-driven autoimmune diseases. * Lead Program: ORN-252 (CAR-T therapy targeting CD19) * Focus: B cell-driven autoimmune diseases * Technology: Engineered circular RNA paired with lipid nanoparticles The potential of Orna's circular RNA platform is significant. Early research indicates it may offer more durable protein expression compared to existing therapies, which could lead to novel treatment options that are not feasible with traditional RNA or cell therapies. Expert insights. Dr. Francisco Ramírez-Valle, Senior Vice President at Lilly, emphasized the promise of cell therapies for autoimmune patients. However, he acknowledged the complexity and cost associated with ex vivo treatment methods. "They make it challenging to deliver these breakthroughs to a broader patient population," he noted. The acquisition aligns with Lilly's commitment to pioneering innovative therapeutics. Joe Bolen, CEO of Orna, expressed enthusiasm about combining their technology with Lilly's expertise in patient-centric therapeutics. Corporate partnerships. In terms of legal and financial counsel, Paul, Weiss, Rifkind, Wharton & Garrison LLP represents Lilly, while Lazard is advising Orna. Goodwin Procter LLP also supports Orna in this transaction. About Lilly and Orna Therapeutics. * Lilly: A leader in scientific innovation aimed at improving global health, focusing on diseases like diabetes, Alzheimer's, and various immune disorders. * Orna Therapeutics: Focused on revolutionizing RNA medicine with their oRNA(R) technology, offering advantages in production and protein expression. This acquisition stands to significantly advance Lilly's pipeline in genetic medicine and in vivo cell engineering, ultimately aiming to provide new therapeutic solutions for patients in need.

Eli Lilly to buy Orna Therapeutics, which focuses on ‘in vivo’ CAR-T for autoimmune diseases, for $2.4 billion